Actively Recruiting
Effects of Dexamethasone on Heart and Lung Health in Extremely Preterm Infants Born Before 29 Weeks
Led by McGill University Health Centre/Research Institute of the McGill University Health Centre · Updated on 2025-06-17
21
Participants Needed
1
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating how dexamethasone affects the heart and lungs of extremely premature infants born before 29 weeks of gestation. The study focuses on changes in cardiac structure, especially left ventricular hypertrophy, and lung water content, which may reflect lung inflammation and fluid retention. It also explores secondary effects on heart function, ductus arteriosus, body growth, and heart rate variability in this vulnerable population. The study is observational and will monitor infants treated with dexamethasone for lung disease. Heart and lung assessments include echocardiography and lung ultrasound performed before and after steroid treatment. Electrocardiograms will track heart rate variability, and body growth measurements will be collected at multiple time points before and after treatment, extending up to 36 weeks post-menstrual age. Participants will undergo scheduled imaging and clinical evaluations to measure heart muscle thickness, heart function, lung fluid levels, duct size, and other cardiac parameters. Growth and cortisol levels will also be tracked over a 12-month period. The study aims to understand how dexamethasone influences heart and lung health in premature infants, with data collection spanning multiple weeks and concluding with comprehensive outcome assessments.
CONDITIONS
Brief Title
Postnatal Steroids Effects on Cardiac Function in Extremely Preterm
Research Team
G
Gabriel Altit
J
Jessica Simoneau
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here